Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease

Inclusion Criteria: * Age greater than or equal to 18 years. * Patients on HPN for chronic benign intestinal failure: with a degree of HPN dependence ≥ two cycles of PN per week with at least one ternary infusion (comprising lipids) per week with a maximum lipid intake of 40 grams per ternary infusion * Expected duration of HPN dependence greater than 18 weeks at the time of inclusion. * Receiving HPN for at least 12 weeks in one of the three study centres, which is a sufficient period to allow resolution of any drug-induced or septic cholestasis and cytolysis related to a previous hospitalisation. * Presence of PNALD, defined by an abnormality of at least two of the five liver function tests performed (conjugated bilirubin, gamma glutamyltransferase, alkaline phosphatase, AST, ALT). * Stable patient with no infection during the six weeks preceding inclusion. * Medical examination performed before inclusion. * Written informed consent. * Covered by French national health insurance. Exclusion Criteria: * Active cancer, regardless of the primary site. * Uncontrolled cardiopulmonary insufficiency. * Decompensated cirrhosis. * Severe renal failure. * Uncontrolled diabetes or endocrinopathy. * Hyperlipoproteinaemia and hypertriglyceridaemia (≥ 3 mmol/L). * Other causes of liver disease (biliary obstruction, alcohol, hepatitis B virus, hepatitis C virus, CMV, hepatotoxic drugs). * Systemic corticosteroid therapy or biotherapy (anti-TNF). * Pregnant women or nursing mothers. * …